Drug intelligence / Profile preview

MAR-FG-001

Development stage: Preclinical
Lead developer: Marizyme
Administration: Subcutaneous

Overview

MAR-FG-001 is a preclinical-stage graft preservation solution developed by Marizyme. It is specifically designed for use in fat grafting procedures within plastic and reconstructive surgery to mitigate ischemic injury and oxidative stress in harvested adipose tissue. During the fat grafting process, fat cells are temporarily deprived of blood supply, leading to cellular damage and reduced graft survival; MAR-FG-001 aims to enhance the viability and long-term retention of the grafted fat by providing a protective environment during the ex vivo period.

Other names: MAR-FG-001MAR-FG001MAR-FG 001

Beyond the preview

Go deeper on MAR-FG-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAR-FG-001.

Explore the full profile